Hosted on MSN16d
FDA accepts Sentynl’s Menkes disease therapy NDA for priority review
Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.
Businessworld17d
Zydus Lifesciences Stock Rallies 5% On USFDA Approval, CVS Caremark Deal
The stock price of Zydus Lifesciences surged over 5 per cent in the Tuesday trading session after the drugmaker’s wholly owned subsidiary, Sentynl Therapeutics, received U.S. Food and Drug ...
The Pharma Letter17d
FDA to give speedy review of Menkes disease drug
The therapy would be the first treatment for Menkes disease, a rare, fatal pediatric disorder caused by mutations in the copper transporter gene ATP7A. The application has been granted Priority Review ...
Pharmaceutical Technology17d
FDA accepts Sentynl’s Menkes disease therapy NDA for priority review
A rare genetic disorder affecting copper levels in the body, Menkes disease is caused by mutations in the ATPase Copper Transporting Alpha (ATP7A) gene. Give your business an edge with our leading ...
Monthly Prescribing Reference18d
SubQ Copper Histidinate Formulation Gets Priority Review for Menkes Disease
Copper histidinate is expected to improve neurodevelopmental outcomes and survival in patients with Menkes disease, an X-linked recessive disease caused by mutations of the ATP7A copper ...